Lung Cancer Clinical Trial
Identification of Circulating Tumor Cells in the Peripheral Blood of Lung Cancer Patients
Summary
The primary aim of this study is to determine whether we can identify human lung cancer tumor cells in the peripheral blood of lung cancer patients.
Full Description
The purpose of this study is to determine whether we can identify lung cancer cells circulating in the peripheral blood of lung cancer patients using cell surface markers found on cancer cells such as CD44 and epithelial specific antigen.
Eligibility Criteria
Inclusion Criteria:Inclusion Criteria:Inclusion Criteria (Cases):
Advanced stage (IIIB with malignant effusion or IV) histologically or cytologically confirmed NSCLC
Patients must be newly diagnosed (untreated) or have evidence of disease progression at the time of sample collection
ability to sign informed consent
at least 18 years of age
Inclusion Criteria (Controls):
no known prior or active malignancy
ability to sign informed consent
at least 18 years of age Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years Exclusion Criteria:1. history of any other cancer other than non-melanoma skin cancer within the last 5 years
2. pregnant women
Check Your Eligibility
Let’s see if you might be eligible for this study.
What is your age and gender ?
There is 1 Location for this study
Stanford California, 94305, United States
How clear is this clinincal trial information?

Please confirm you are a US based health care provider:
Yes, I am a health care Provider No, I am not a health care providerSign Up Now.
Take Control of Your Disease Journey.
Sign up now for expert patient guides, personalized treatment options, and cutting-edge insights that can help you push for the best care plan.